Ovarian cancer is an aggressive disease that is frequently detected at advanced stages and
is initially very responsive to platinum-based chemotherapy. However, the majority of …

In 2014, FIGO's Committee for Gynecologic Oncology revised the staging of ovarian cancer,
incorporating ovarian, fallopian tube, and peritoneal cancer into the same system. Most of …

The development of guidelines recommendations is one of the core activities of the
European Society for Medical Oncology (ESMO) and European Society of Gynaecologial …

Ovarian cancer is not a single disease and can be subdivided into at least five different
histological subtypes that have different identifiable risk factors, cells of origin, molecular …

Background Platinum-based chemotherapy doublets are a standard of care for women with
ovarian cancer recurring 6 months after completion of initial therapy. In this study, we aimed …

Despite optimal surgery and appropriate first-line chemotherapy,∼ 70%–80% of patients
with epithelial ovarian cancer will develop disease relapse. The same modalities as used …

The drivers of recurrence and resistance in ovarian high grade serous carcinoma remain
unclear. We investigate the acquisition of resistance by collecting tumour biopsies from a …

Purpose AZD1775 is a first-in-class, potent, and selective inhibitor of WEE1 with proof of
chemopotentiation in p53-deficient tumors in preclinical models. In a phase I study, the …

Importance Platinum-based chemotherapy has been the standard of care for ovarian cancer
for the past 3 decades. Although most patients respond to platinum-based treatment …

At present, chemotherapy remains to be one of the most important therapeutic approaches
for malignant tumors. The tumor microenvironment (TME)-responsive intelligent drug …